Novel Sonodynamic Therapy Demonstrates Promising Safety and Efficacy in Glioblastoma Treatment
• Initial clinical results show sonodynamic therapy successfully induced tumor cell death in three newly diagnosed glioblastoma patients without harming healthy brain tissue or causing adverse events.
• In a phase 1/2 trial for recurrent high-grade gliomas, the therapy significantly improved survival outcomes, with median overall survival reaching 15.7 months compared to historical 6-8 months.
• The non-invasive treatment combines low-intensity diffuse ultrasound with oral 5-ALA, offering potential breakthrough advantages by targeting cancer cells across the entire brain hemisphere without requiring imaging or sedation.
Alpheus Medical's Sonodynamic Therapy Shows Promise in Recurrent High-Grade Gliomas
• Alpheus Medical announced positive Phase 1/2 trial results for its sonodynamic therapy (SDT) in recurrent high-grade gliomas, demonstrating a strong safety profile.
• The trial showed extended median overall survival (15.7 months) and progression-free survival (5.5 months) compared to historical data for this aggressive brain cancer.
• Alpheus's SDT combines low-intensity ultrasound with oral 5-aminolevulinic acid, offering a non-invasive treatment option that can be administered in an outpatient setting.
• A randomized, controlled trial is planned for 2025 to further evaluate the efficacy of Alpheus Medical's SDT platform in treating recurrent high-grade gliomas.
© Copyright 2025. All Rights Reserved by MedPath